HEPATITIS AND PNEUMONITIS DURIN ADALIMUMAB THERAPY IN CROHN? DISEASE: mind the histoplasmosis!

HEPATITIS AND PNEUMONITIS DURIN ADALIMUMAB THERAPY IN CROHN? DISEASE: mind the histoplasmosis!

Context Tumor necrosis factor-alpha (TNF-α) inhibitor therapy plays a pivotal role in the management of moderate to severe inflammatory bowel disease. Because of the role of TNF-α in the host defenses, anti-TNF therapy has been associated with an increase the risks of granulomatous infections. Obj...

Full description

Bibliographic Details
Main Authors:	Bruno do Valle PINHEIRO, Áureo de Almeida DELGADO, Julio Maria Fonseca CHEBLI
Format:	Article
Language:	English
Published:	Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE) 2014-03-01
Series:	Arquivos de Gastroenterologia
Subjects:	Doença de Crohn Fator de Necrose Tumoral-alfa Adalimumabe Histoplasmose Hepatite
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032014000100073&lng=en&tlng=en

Similar Items

SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB
by: Mariella BAU, et al.
Published: (2017-09-01)

Current management of fistulizing perianal Crohn’s disease based on serum anti-tumor necrosis factor levels and magnetic resonance imaging monitoring
by: Felipe Bernardi Wolker, et al.
Published: (2020-10-01)

PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN Crohn’s DISEASE: a Brazilian multicenter observational study
by: Paulo Gustavo KOTZE, et al.
Published: (2014-12-01)

ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN?S DISEASE: results of a Latin American single-center observational study
by: Paulo Gustavo KOTZE, et al.
Published: (2014-03-01)

CROHN'S DISEASE: GENERAL CHARACTERISTICS AND TREATMENT WITH ADALIMUMABE BIOPHARMACEUTICAL
by: S. A. Marques, et al.
Published: (2018-02-01)

Crohn's Disease: current state of biological therapy Doença de Crohn: estado atual da terapia biológica
by: Júlio César Monteiro Santos Júnior
Published: (2011-12-01)

Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series
by: Paulo Gustavo Kotze, et al.
Published: (2011-09-01)

Erupção liquenóide: secundária ao uso de adalimumabe?
by: Maria Cristina Bezzan Goldschmidt, et al.

Adalimumab and azathioprine in the prevention of postoperative crohn’s disease recurrence
by: A. V. Poletova, et al.
Published: (2020-10-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
by: Lankai Cathy Xu, et al.
Published: (2023-03-01)

Crohn’s Disease Associated Pyoderma Gangrenosum Treated with Adalimumab
by: Despoina Kakagia, et al.
Published: (2012-03-01)

Histopatologia da hepatite de Lábrea
by: Zilton A Andrade, et al.
Published: (1983-03-01)

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
by: Wei-Chen Lin, et al.
Published: (2017-10-01)

Tratamiento de inducción y mantenimiento con adalimumab en la enfermedad de Crohn: un estudio abierto Adalimumab induction and maintenance therapy from Crohn's diseas: An open-label study
by: N. López Palacios, et al.
Published: (2008-11-01)

Listeria Monocytogenes Brain Abscess in Crohn’s Disease Treated with Adalimumab
by: Amporn Atsawarungruangkit, et al.
Published: (2017-11-01)

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar
by: M. Barreiro-de Acosta, et al.
Published: (2010-10-01)

Crohn's-like disease in a patient with common variable immunodeficiency treated with azathioprine and adalimumab
by: Juan María Vázquez-Morón, et al.
Published: (2013-06-01)

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
by: Chen-Wang Chang, et al.
Published: (2014-10-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
by: Taketo Suzuki, et al.
Published: (2019-02-01)

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
by: Liang Chen, et al.
Published: (2022-08-01)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
by: Kai-Chun Wu, et al.
Published: (2016-04-01)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

Efeito antioxidante do Resveratrol na função vascular
by: Catarina Freitas, et al.
Published: (2023-04-01)

Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab
by: Cristina Saro, et al.

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?
by: Beraldo RF, et al.
Published: (2020-08-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab
by: Glenn Harvin, et al.
Published: (2016-05-01)

Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study
by: Carmen-Monica Preda, et al.

Hidradenite supurativa tratada com infliximabe Hidradenitis suppurativa treated with infliximab
by: Daniel Lago Obadia, et al.
Published: (2009-12-01)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
by: Juntao Yin, et al.
Published: (2022-09-01)

Identification of Novel Loci Involved in Adalimumab Response in Crohn’s Disease Patients Using Integration of Genome Profiling and Isoform-Level Immune-Cell Deconvoluted Transcriptome Profiling of Colon Tissue
by: Mario Gorenjak, et al.
Published: (2022-09-01)

HISTOPLASMOSE CUTÂNEA EXTENSA ASSOCIADA À PÊNFIGO VULGAR EM PACIENTE IMUNOCOMPETENTE
by: Roberta Lestch da Silveira, et al.
Published: (2023-10-01)

Avaliação do efeito da esplenectomia e auto-implante esplênico sobre algumas funções de monócitos em crianças com esquistossomose mansônica
by: Carlos T. Brandt, et al.
Published: (2005-02-01)

Early Initiation of Adalimumab Significantly Diminishes Postoperative Crohn’s Disease Endoscopic Recurrence and Is Superior to 6-Mercaptopurine Therapy: An Open-Label, Randomized Controlled Study
by: Ayal Hirsch, et al.
Published: (2023-12-01)

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
by: Arne Carlsen, et al.
Published: (2020-06-01)

A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease
by: Víctor Manuel Navas-López, et al.
Published: (2018-02-01)

Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
by: Mauro Mastronardi, et al.
Published: (2019-11-01)